Spyre Therapeutics Prices Public Offering for $403M Gross Proceeds

Spyre Therapeutics, Inc. announced the pricing of its underwritten public offering, selling 6,500,000 shares of common stock at $62.00 per share. This offering is expected to generate gross proceeds of approximately $403.0 million for the company, before deducting underwriting discounts and other expenses. Additionally, the underwriters have been granted a 30-day option to purchase up to an extra $60.5 million worth of common stock at the public offering price.